Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Statins, What Next?

This article was originally published in Start Up

Executive Summary

As statins go generic, a host of companies are hunting out new treatments for cholesterol control. They're not put off by recent setbacks, given the huge remaining unmet need and commercial opportunity. Many new companies are still trying to lower LDL and/or raise HDL, but anti-inflammatory approaches are increasingly popular too, as scientists better understand the nature and process of plaque formation.

Related Content

Aterovax SA
Merck Taking Aggressive Approach To Cardiovascular Development
FDA Finds Statins Not Linked To ALS; When Can A False Alarm Be Turned Off?
Start-Up Quarterly Statistics, Q1 2008
Abbott’s Phase III Fenofibrate Works With Statins
The Unsung Vytorin Victim: Primary-Care Marketing
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
Generic Statins Make Sense In Lower CV Risk Patients, WellPoint Asserts
In RNAi, Technology Proliferates Beyond the Big Two
Metabolex and J&J: Why Biotech's Pipelines Needs Pharma's


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts